Observational study to evaluate the use of cannabis extract (THC/CBD) for non-motor symptoms in Parkinson's patients

Observational study to evaluate the use of cannabis extract (THC/CBD) for non-motor symptoms in Parkinson's patients - CAMINO

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00035853

Enrollment

200

Registered

2025-01-09

Start date

2025-01-03

Completion date

Unknown

Last updated

2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-motor symptoms of Parkinson's disease

Interventions

Group 1: 200 Parkinson's patients who were prescribed medicinal cannabis extract (10:10) by their treating physician to treat the target symptoms (pain, sleep disorders, depression, stress and anxiety

Eligibility

Sex/Gender

All

Age

23 Years to No maximum

Inclusion criteria

Inclusion criteria: Parkinson's disease non-motor disorders (pain, sleep disorders, depression, stress and anxiety) Consent to therapy with medicinal cannabis

Exclusion criteria

Exclusion criteria: Pregnancy/breastfeeding period Existing care according to § 1814 BGB

Design outcomes

Primary

Measure	Time frame
Change in target symptoms (pain, sleep disorders, depression, stress and anxiety) after 12 weeks of treatment with a cannabis extract (10:10 - THC:CBD)	—

Secondary

Measure	Time frame
Improving quality of life and motor disorders in Parkinson's disease Reasons for discontinuing therapy Occurrence of side effects	—

Countries

Germany

Contacts

Public ContactThomas Vaterrodt

DZMC

tv@v3ventures.eu015206476877

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 7, 2026